EUVIMEDEUVIMED entdecken
Crossref

Tolerability and pharmacokinetics of leritrelvir in Chinese participants with severe renal impairment and healthy matched control subjects

Zi-Yi Zhou iD, Xiao-Qing Wen, Wen-Rui Zhang, Yue-Yuan Huang, Hai-Jun Li, You-Yun Li, J I-Yi Huang, Xi Luo

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70474 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Zi-Yi Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Drug Clinical Trial Institution, The First Affiliated Hospital of Xiamen University, Xiamen, China. Hauptthemen laut MEDLINE: Renal Insufficiency, Cysteine Proteinase Inhibitors. Die Arbeit nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The study's aim is to evaluate the pharmacokinetics (PK) and safety of leritrelvir, a novel 3‐chymotrypsin‐like cysteine protease (3CLpro) inhibitor, in patients with severe renal impairment (RI; n = 7) compared to healthy controls ( n = 8).

Methods

This nonrandomized, open‐label, parallel‐group, single‐dose trial included primary PK endpoints ( C max , AUC 0‐t , AUC 0‐∞ , t 1/2 ) and safety endpoints (AEs, vital signs, laboratory tests). Log‐transformed PK parameters were analysed by ANOVA to calculate GMRs (90% confidence intervals [CIs]) for group comparisons, with statistical significance assessed for exposure differences.

Results

PK analysis revealed similar median time‐to‐peak concentration ( T max ) but a reduced elimination half‐life (t 1/2 ) in the RI group (4.20 h vs . 5.09 h). The geometric mean ratios (90% CI) of systemic exposure parameters indicated increases of 30.34% for C max , 54.19% for AUC 0‐t , and 56.83% for AUC 0‐∞ in the RI group compared to controls.

Conclusions

Modest PK alterations in severe renal impairment are clinically insignificant given leritrelvir's wide therapeutic index. The drug is well‐tolerated (mild‐to‐moderate, short‐duration AEs), and no dose adjustment is needed for patients with renal impairment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal InsufficiencyCysteine Proteinase InhibitorsHumansMaleFemaleMiddle AgedArea Under CurveAdultHalf-LifeAgedSeverity of Illness IndexChinaEast Asian People

Stichwörter der Autor:innen

COVID‐19leritrelvirpharmacokineticsrenal impairmentsafety

Substanzen

Cysteine Proteinase Inhibitors

Autor:innen und Institutionen

  • Drug Clinical Trial Institution, The First Affiliated Hospital of Xiamen University, Xiamen, China.
  • School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
  • Department of Anatomy and Neurobiology, School of Basic Medical Sciences, Central South University, Changsha, China.
  • Guangdong Raynovent Biotech Co., Ltd, Guangzhou, China.
  • Department of Nephrology, Fujian Clinical Research Center for Chronic Glomerular Disease, The First Affiliated Hospital of Xiamen University, Xiamen, China.

ORCID-Profile: Zi-Yi Zhou

Zitieren

APA

Zhou, Z. Y., Wen, X. Q., Zhang, W. R., Huang, Y. Y., Li, H. J., Li, Y. Y., Huang, J. I., & Luo, X. (2026). Tolerability and pharmacokinetics of leritrelvir in Chinese participants with severe renal impairment and healthy matched control subjects. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70474

Vancouver

Zhou ZY, Wen XQ, Zhang WR, Huang YY, Li HJ, Li YY, et al. Tolerability and pharmacokinetics of leritrelvir in Chinese participants with severe renal impairment and healthy matched control subjects. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70474

BibTeX
@article{Zhou2026,
  author = {Zhou, Zi-Yi and Wen, Xiao-Qing and Zhang, Wen-Rui and Huang, Yue-Yuan and Li, Hai-Jun and Li, You-Yun and Huang, J I-Yi and Luo, Xi},
  title = {Tolerability and pharmacokinetics of leritrelvir in Chinese participants with severe renal impairment and healthy matched control subjects},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70474}
}
Kostenlos starten →